Filing Flows › Ultragenyx Pharmaceutical (RARE) › Q3 2026 › vs Q3 2025
Ultragenyx Pharmaceutical (RARE) Q3 2026 vs Q3 2025 (year over year)
Ultragenyx Pharmaceutical's revenue rose $13.0M (+8%) from $160M in Q3 2025 to $173M in Q3 2026. The biggest changes: Product +$10.0M (+11%); Royalty +$3.0M (+5%).
Ultragenyx Pharmaceutical, Q3 2026: revenue $173M (+8% year over year), operating margin -63.6%, net loss $118M, operating cash flow −$43.0M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Product | $105M | $95.0M | $10.0M | +11% |
| Royalty | $68.0M | $65.0M | $3.0M | +5% |
| Revenue | $173M | $160M | $13.0M | +8% |
| Income tax benefit | $9.0M | −$1.0M | $10.0M | — |
| Net loss | $118M | $180M | −$62.0M | -34% |
| Costs & expenses | $300M | $340M | −$40.0M | -12% |
| Operating costs | $283M | $331M | −$48.0M | -15% |
| Interest & other, net | $17.0M | $8.0M | $9.0M | +112% |
| Research & development | $154M | $216M | −$62.0M | -29% |
| SG&A | $97.0M | $87.0M | $10.0M | +11% |
| Other operating costs | $32.0M | $28.0M | $4.0M | +14% |
| Operating cash sources | $118M | $180M | −$62.0M | -34% |
| Depreciation & amortization | $9.0M | $8.0M | $1.0M | +12% |
| Share-based compensation | $34.0M | $37.0M | −$3.0M | -8% |
| Working capital & other | $32.0M | $44.0M | −$12.0M | -27% |
| Cash used in operations | $43.0M | $91.0M | −$48.0M | -53% |
| Net loss absorbed | $118M | $180M | −$62.0M | -34% |
Questions
How much did Ultragenyx Pharmaceutical's revenue grow year over year in Q3 2026?
Ultragenyx Pharmaceutical's revenue rose $13.0M (+8%) from $160M in Q3 2025 to $173M in Q3 2026.
What drove Ultragenyx Pharmaceutical's revenue change in Q3 2026?
Product +$10.0M (+11%); Royalty +$3.0M (+5%).